Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024 17:21 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 02, 2024 16:05 ET
|
Eledon Pharmaceuticals, Inc.
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
June 03, 2024 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 09, 2024 07:30 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 09, 2024 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024 16:56 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024 19:01 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024 16:40 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023 18:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)